摘要
Aim To prepare a self-emulsifying microemulsion of 9-nitrocamptothecin (9-NC ME) for intravenous injection and investi- gation of its pharmacokinetic profiles in normal SD rats. Methods 9-NC ME was optimized in terms of droplet size and lack of drug precipitation following aqueous dilution using a pseudo-ternary phase diagram. Physicochemical properties of 9-NC ME were evaluated. 9-NC ME was intravenously administered via tail vein in healthy rats. Results A stable microemulsion was formulated consisted of soybean oil as oil phase, EPC/Tween-80 as emulsifier, and anhydrous ethanol as co-emulsifier. The droplets of the microemulsion were spherical shape with mean diameter of 38.3 ± 4.0 nm after 1:20 dilution with 5% glucose injection. The pharmacokinetic parameters of 9-NC ME after intravenous administration in rats were t1/2 of 0.97 ± 0.14 h, A UC0-8 of 372.77 ±49.62 ng·h·mL^-1 and MRT of 1.40 ± 0.21 h which were 1.4-fold, 1.65-fold, and 1.4-fold more than those of 9-NC solution (P〈0.01). Conclusion The results suggested that 9-NC ME was a promising drug delivery system and it was expected to provide a novel 9-NC injection for cancer patients.
目的制备9-硝基喜树碱自微乳化静脉注射给药系统(9-NCME),并考察其在大鼠体内的药动学情况。方法采用伪三元相图确定油相制剂组成,以正交设计优化处方组成,评价了9-NCME制剂的稳定性,并考察了正常大鼠尾静脉注射后体内的药动学行为。结果以注射用大豆油为油相、EPC/Tween80为乳化剂、无水乙醇为助乳化剂等成分组成的新型注射剂9-NCME,在临用前用5%葡萄糖注射液稀释20倍后可自发形成平均粒径38.3±4.0nm稳定微乳,大鼠尾静脉给予9-NCME药动学参数为:t1/2(0.97±0.14h),AUC0–8(372.77±49.62ng·h·mL–1)andMRT(1.40±0.21h),分别是对照溶液剂的1.4、1.65和1.4倍(P<0.01)。结论9-NCME具有较好的物理和化学稳定性,有望成为新型的9-NC静脉注射剂。
基金
National Natural Science Foundation of China (GrantNo.30430760)
the 985 projects (Phase II) of the State Key Labo-ratory of Natural and Biomimetic Drugs (Peking University, China).